文献速递白血病

CD81敲除促进急性淋巴细胞白血病化疗敏感性并破坏体内归巢与植入

CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究探讨CD81在急性淋巴细胞白血病骨髓微环境介导的化疗保护中的作用。CD81敲除可诱导化疗敏感性、减少细胞黏附并破坏体内骨髓归巢与植入,其机制涉及Bruton酪氨酸激酶信号和p53介导的细胞死亡。阿扎胞苷与帕比司他联合用药可通过调节CD81表面表达增强化疗反应。

要点

  • CD81敲除增强B-ALL化疗敏感性并破坏骨髓归巢与植入。
  • CD81通过调控BTK信号和p53介导的细胞死亡发挥作用。
  • 阿扎胞苷联合帕比司他通过调节CD81表面表达增强化疗反应。

核心结论

  • CD81在骨髓微环境诱导的化疗保护中起新作用,其敲除可诱导化疗敏感性并破坏体内骨髓归巢与植入。
  • 阿扎胞苷与帕比司他联合用药通过调节CD81表面表达使ALL细胞对化疗敏感。

研究设计与样本

  • 研究采用CD81敲除的B-ALL细胞模型及患者来源异种移植模型进行体内外实验。

主要发现

  • CD81敲除诱导化疗敏感性、减少细胞黏附并破坏体内骨髓归巢与植入。
  • CD81敲除的化疗增敏作用通过控制Bruton酪氨酸激酶信号和诱导p53介导的细胞死亡实现。
  • 阿扎胞苷与帕比司他联合用药调节CD81表面表达,促进ALL细胞从骨髓向外周血动员并增加化疗反应。

临床怎么用

  • 靶向CD81或其相关信号可能为克服ALL骨髓微环境介导的化疗耐药提供策略。
  • 阿扎胞苷联合帕比司他可通过调节CD81增强ALL化疗敏感性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse remains a major obstacle to achieving 100% overall survival rate in pediatric hematologic malignancies like acute lymphoblastic leukemia (ALL). Relapse often results from the development of chemoresistance. One of the mechanisms of chemoresistance involves ALL cell interactions with the bone marrow (BM) microenvironment, providing a sanctuary. This phenomenon is known as BM microenvironment-induced chemoprotection. Members of the transmembrane 4 superfamily (tetraspanins; TSPANs) are known to mediate microenvironmental interactions and have been extensively studied in solid tumors. Although the TSPAN family member CD81 is a minimal residual disease marker, its biological role in ALL is not well characterized. We show for the first time that CD81 knockout induces chemosensitivity, reduces cellular adhesion, and disrupts in vivo BM homing and engraftment in B-ALL. This chemosensitization is mediated through control of Bruton tyrosine kinase signaling and induction of p53-mediated cell death. We then show how CD81-related signaling can be disrupted by treatment with the epigenetic drug combination of DNA hypomethylating agent azacitidine (aza) and histone deacetylase inhibitor panobinostat (pano), which we previously used to sensitize ALL cells to chemotherapy under conditions that promote BM microenvironment-induced chemoprotection. Aza/pano-mediated modulation of CD81 surface expression is involved in decreasing BM load by promoting ALL cell mobilization from BM to peripheral blood and increasing response to chemotherapy in disseminated patient-derived xenograft models. This study identifies the novel role of CD81 in BM microenvironment-induced chemoprotection and delineates the mechanism by which aza/pano successfully sensitizes ALL cells via modulation of CD81.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Quagliano A, Gopalakrishnapillai A, Kolb EA, et al. CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia. Blood Adv. 2020. PMID: 32926125. doi:10.1182/bloodadvances.2020001592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。